-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Downgrades Crinetics Pharmaceuticals to Neutral, Raises Price Target to $85

Benzinga·07/28/2026 12:27:33
语音播报
UBS analyst Ashwani Verma downgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) from Buy to Neutral and raises the price target from $55 to $85.